Coronavirus company news summary – Guardant Health receives EUA from FDA – Restalyst launches new Covid-19 antibody test

25 August 2020 (Last Updated August 25th, 2020 09:23)

AXIM Biotechnologies has signed an agreement with Empowered Diagnostics for the licensing, manufacturing and distribution of its rapid diagnostic test, which measures the levels of SARS-CoV-2 functional neutralising antibodies. These antibodies prevent Covid-19 from entering the cells of the host. The lateral flow assay tests will be manufactured by Empowered Diagnostics as the Tru-19 Neutralizing Antibody Test.

Guardant Health has received Emergency Use Authorisation from the US Food and Drug Administration for its rt-PCR-seq test, which detects the presence of SARS-CoV-2. The test detects the presence of SARS-CoV-2 nucleic acid from respiratory samples. The test is available for Guardant Health employees and select partner organisations. The validated limit of detection (LoD) of the test is 125 copies per mL and it provides results the next day.

Mobile Health has launched a new return-to-the-workplace service that can screen the employees for Covid-19 before they commence working on-site. The programme also includes the check-in software of Mobile Health, which employees are mandated to complete remotely, which provides a QR code to display. Schools and other organisations can also use the technology.

Singapore-based Restalyst has announced the development of Covid-19 antibody test, COVID19N-REAAD, that is expected to establish disease prevalence in populations and the risk factors of exposure. This will help the healthcare authorities to determine the efficacy of control measures in place for Covid-19 and streamline them in the long run. The insights regarding population segments which are more prone to infection could aid in the future roll out of vaccines.